Ravi Viswanathan - Net Worth and Insider Trading

Ravi Viswanathan Net Worth

The estimated net worth of Ravi Viswanathan is at least $1.4 Billion dollars as of 2024-04-27. Ravi Viswanathan is the 10% Owner of Tesaro Inc and owns about 10,420,645 shares of Tesaro Inc (TSRO) stock worth over $781 Million. Ravi Viswanathan is the 10% Owner of Rhythm Pharmaceuticals Inc and owns about 4,909,956 shares of Rhythm Pharmaceuticals Inc (RYTM) stock worth over $188 Million. Ravi Viswanathan is also the 10% Owner of Ra Pharmaceuticals Inc and owns about 3,490,073 shares of Ra Pharmaceuticals Inc (RARX) stock worth over $167 Million. Besides these, Ravi Viswanathan also holds Adaptimmune Therapeutics PLC (ADAP) , Ardelyx Inc (ARDX) , AVEO Pharmaceuticals Inc (AVEO) , Mersana Therapeutics Inc (MRSN) , Millennial Media Inc (MM) , Epizyme Inc (EPZM) , Surface Oncology Inc (SURF) , Dermira Inc (DERM) , Interleukin Genetics Inc (ILIU) , Achaogen Inc (AKAOQ) , Clovis Oncology Inc (CLVSQ) , TRACON Pharmaceuticals Inc (TCON) , ARCA biopharma Inc (ABIO) , Appian Corp (APPN) . Details can be seen in Ravi Viswanathan's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Ravi Viswanathan has not made any transactions after 2018-09-07 and currently still holds the listed stock(s).

Transaction Summary of Ravi Viswanathan

To

Ravi Viswanathan Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Ravi Viswanathan owns 39 companies in total, including PhaseBio Pharmaceuticals Inc (PHASQ) , Marker Therapeutics Inc (MRKR) , and Elastic NV (ESTC) among others .

Click here to see the complete history of Ravi Viswanathan’s form 4 insider trades.

Insider Ownership Summary of Ravi Viswanathan

Ticker Comapny Transaction Date Type of Owner
PHASQ PhaseBio Pharmaceuticals Inc 2018-10-17 10 percent owner
MRKR Marker Therapeutics Inc 2018-10-17 10 percent owner
ESTC Elastic NV 2018-10-04 10 percent owner
ADAP Adaptimmune Therapeutics PLC 2018-09-07 10 percent owner
AVEO AVEO Pharmaceuticals Inc 2018-08-21 10 percent owner
ARDX Ardelyx Inc 2016-07-18 10 percent owner
MULE MuleSoft Inc 2018-05-01 10 percent owner
SURF Surface Oncology Inc 2018-04-23 10 percent owner
TCON TRACON Pharmaceuticals Inc 2018-03-27 10 percent owner
CASC Cascadian Therapeutics Inc 2018-03-09 10 percent owner
TSRO Tesaro Inc 2018-03-06 10 percent owner
ABIO ARCA biopharma Inc 2018-02-26 10 percent owner
RARX Ra Pharmaceuticals Inc 2018-02-16 10 percent owner
APPN Appian Corp 2017-11-27 10 percent owner
SYBX Synlogic Inc 2015-09-30 10 percent owner
GNCAQ Genocea Biosciences Inc 2018-01-19 10 percent owner
SBBP Strongbridge Biopharma PLC 2018-01-01 10 percent owner
XFOR X4 Pharmaceuticals Inc 2017-11-20 10 percent owner
CRCM Care.com Inc 2017-11-06 10 percent owner
RYTM Rhythm Pharmaceuticals Inc 2017-10-10 10 percent owner
RGLS Regulus Therapeutics Inc 2017-07-24 10 percent owner
MRSN Mersana Therapeutics Inc 2017-07-03 10 percent owner
AKAOQ Achaogen Inc 2016-12-19 10 percent owner
ROKA Sorrento Tech Inc 2016-09-21 10 percent owner
ILIU Interleukin Genetics Inc 2016-07-29 10 percent owner
EPZM Epizyme Inc 2016-01-12 10 percent owner
AVTX Avalo Therapeutics Inc 2015-10-14 10 percent owner
CSBR Champions Oncology Inc 2015-03-11 10 percent owner
BOX Box Inc 2015-01-22 10 percent owner
CVT Cvent Inc 2014-11-25 10 percent owner
DERM Dermira Inc 2014-10-08 10 percent owner
LOXO Loxo Oncology Inc 2014-08-06 10 percent owner
HIVE Aerohive Networks Inc 2014-04-02 10 percent owner
GLYC GlycoMimetics Inc 2014-01-09 10 percent owner
CLVSQ Clovis Oncology Inc 2011-11-21 10 percent owner
WDAY Workday Inc 2012-10-11 10 percent owner
MM Millennial Media Inc 2012-10-29 10 percent owner
DUOL Duolingo Inc 2022-06-24 10 percent owner
GGNNQ Genocea Biosciences Inc 2018-01-19 10 percent owner

Ravi Viswanathan Latest Holdings Summary

Ravi Viswanathan currently owns a total of 17 stocks. Among these stocks, Ravi Viswanathan owns 10,420,645 shares of Tesaro Inc (TSRO) as of March 6, 2018, with a value of $781 Million and a weighting of 57.74%. Ravi Viswanathan owns 4,909,956 shares of Rhythm Pharmaceuticals Inc (RYTM) as of October 10, 2017, with a value of $188 Million and a weighting of 13.89%. Ravi Viswanathan also owns 3,490,073 shares of Ra Pharmaceuticals Inc (RARX) as of October 31, 2016, with a value of $167 Million and a weighting of 12.38%. The other 14 stocks Adaptimmune Therapeutics PLC (ADAP) , Ardelyx Inc (ARDX) , AVEO Pharmaceuticals Inc (AVEO) , Mersana Therapeutics Inc (MRSN) , Millennial Media Inc (MM) , Epizyme Inc (EPZM) , Surface Oncology Inc (SURF) , Dermira Inc (DERM) , Interleukin Genetics Inc (ILIU) , Achaogen Inc (AKAOQ) , Clovis Oncology Inc (CLVSQ) , TRACON Pharmaceuticals Inc (TCON) , ARCA biopharma Inc (ABIO) , Appian Corp (APPN) have a combined weighting of 15.98% among all his current holdings.

Latest Holdings of Ravi Viswanathan

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
TSRO Tesaro Inc 2018-03-06 10,420,645 74.96 781,131,549
RYTM Rhythm Pharmaceuticals Inc 2017-10-10 4,909,956 38.28 187,953,116
RARX Ra Pharmaceuticals Inc 2016-10-31 3,490,073 47.99 167,488,603
ADAP Adaptimmune Therapeutics PLC 2018-09-07 94,978,668 1.08 102,102,068
ARDX Ardelyx Inc 2016-07-18 5,331,039 6.42 34,225,270
AVEO AVEO Pharmaceuticals Inc 2018-08-21 1,869,804 15.00 28,047,060
MRSN Mersana Therapeutics Inc 2017-07-03 8,140,138 2.94 23,932,006
MM Millennial Media Inc 2012-10-29 8,196,614 1.75 14,344,075
EPZM Epizyme Inc 2016-01-12 6,260,851 1.47 9,203,451
SURF Surface Oncology Inc 2018-04-23 3,312,877 1.07 3,544,778
DERM Dermira Inc 2014-10-02 17,241 18.75 323,269
ILIU Interleukin Genetics Inc 2016-07-29 55,418,811 0.00 249,385
AKAOQ Achaogen Inc 2016-12-19 5,215,128 0.03 130,378
CLVSQ Clovis Oncology Inc 2011-11-21 3,419,671 0.02 51,295
TCON TRACON Pharmaceuticals Inc 2018-03-27 17,330 1.81 31,367
ABIO ARCA biopharma Inc 2018-02-26 0 3.58 0
APPN Appian Corp 2017-11-27 0 37.56 0

Holding Weightings of Ravi Viswanathan


Ravi Viswanathan Form 4 Trading Tracker

According to the SEC Form 4 filings, Ravi Viswanathan has made a total of 0 transactions in Tesaro Inc (TSRO) over the past 5 years. The most-recent trade in Tesaro Inc is the acquisition of 145,532 shares on March 6, 2018, which cost Ravi Viswanathan around $8 Million.

According to the SEC Form 4 filings, Ravi Viswanathan has made a total of 0 transactions in Rhythm Pharmaceuticals Inc (RYTM) over the past 5 years. The most-recent trade in Rhythm Pharmaceuticals Inc is the acquisition of 550,000 shares on October 10, 2017, which cost Ravi Viswanathan around $9 Million.

According to the SEC Form 4 filings, Ravi Viswanathan has made a total of 0 transactions in Ra Pharmaceuticals Inc (RARX) over the past 5 years. The most-recent trade in Ra Pharmaceuticals Inc is the sale of 435 shares on October 31, 2016, which brought Ravi Viswanathan around $5,655.

More details on Ravi Viswanathan's insider transactions can be found in the Insider Trading History of Ravi Viswanathan table.

Insider Trading History of Ravi Viswanathan

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Ravi Viswanathan Trading Performance

GuruFocus tracks the stock performance after each of Ravi Viswanathan's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ravi Viswanathan is 24.93%. GuruFocus also compares Ravi Viswanathan's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ravi Viswanathan within 3 months outperforms 20 times out of 29 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Ravi Viswanathan's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Ravi Viswanathan

Average Return

0.38%

Average return per transaction

Outperforming Transactions

32%

9 out of 28 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 8.63 24.93 24.27 0.38 -22.48 -17.19
Relative Return to S&P 500(%) 7.35 21.05 18.65 -11.31 -31.4 -30

Ravi Viswanathan Ownership Network

Ownership Network List of Ravi Viswanathan

No Data

Ownership Network Relation of Ravi Viswanathan


Ravi Viswanathan Owned Company Details

What does PhaseBio Pharmaceuticals Inc do?

Who are the key executives at PhaseBio Pharmaceuticals Inc?

Ravi Viswanathan is the 10 percent owner of PhaseBio Pharmaceuticals Inc. Other key executives at PhaseBio Pharmaceuticals Inc include 10 percent owner New Enterprise Associates 13 Lp , VP & Human Resources Glen Burkhardt , and Chief Commercial Officer Jonathan Birchall .

PhaseBio Pharmaceuticals Inc (PHASQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of PhaseBio Pharmaceuticals Inc (PHASQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of PhaseBio Pharmaceuticals Inc (PHASQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

PhaseBio Pharmaceuticals Inc (PHASQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

PhaseBio Pharmaceuticals Inc Insider Transactions

No Available Data

Ravi Viswanathan Mailing Address

Above is the net worth, insider trading, and ownership report for Ravi Viswanathan. You might contact Ravi Viswanathan via mailing address: 1954 Greenspring Drive, Suite 600, Timonium Md 21093.

Discussions on Ravi Viswanathan

No discussions yet.